The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]
Marcio Souza
Advertisement
Articles by Marcio Souza
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
2
Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials
3
Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo
4
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
5
